Genomic target selection enables faster development of clinical sequencing tests for disease diagnosis, stratification, and informed therapy selection by allowing smaller, specific regions of the genome to be sequenced and analysed at high depth in a cost-effective manner. Faster, targeted sequencing could also accelerate development of effective therapies for various diseases. Currently available commercial target capture reagents use biotinylated, array-synthesised oligonucleotides to generate DNA or RNA probes, often referred to as “baits.” However, baits that are generated by these methods often present performance challenges, such as failure to capture regions of high GC content.
Targeting the genome
Source: Laboratory News
Image credits: Magazine Cultura
Art and Science of Laboratory Medicine